Table 5 Incidence of major bleeding according to antithrombotic therapy

From: Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

 

N (%)

Total, N = 597 % pts/year (95% CI)

Antiplatelet agents, n = 486 % pts/year (95% CI)

Anticoagulant agents, n = 65 % pts/year (95% CI)

p-valuea

Major bleeding

25 (4)

0.90 (0.61–1.35)

0.94 (0.61–1.44)

0.79 (0.20–3.16)

0.980

 CNS bleeding

8 (1.3)

0.30 (0.15–0.59)

0.35 (0.18–0.70)

0 (0)

0.426

 GI bleeding

8 (1.3)

0.26 (0.12–0.55)

0.26 (0.12–0.59)

0.40 (0.06–2.81)

0.674

 Muscle hematoma

5 (0.8)

0.19 (0.08–0.45)

0.18 (0.07–0.47)

0.39 (0.05–2.77)

0.497

 Epistaxis

4 (0.6)

0.15 (0.06–0.40)

0.13 (0.04–0.41)

0 (0)

0.726

  1. CNS cerebral nervous system, GI gastrointestinal
  2. aTests for differences in incidence rate between antiplatelet agents and anticoagulant agents groups
Back to article page